PathCare is pleased to announce that, from 12 January 2026, we will provide plasma metanephrine (MN), normetanephrine (NMN), and 3-methoxytyramine (3MT) measured using High-Resolution Accurate-Mass (LC-HRAM).

This upgrade aligns our service with international best practice for the biochemical evaluation of catecholamine-secreting tumours.